Connor Clark & Lunn Investment Management Ltd. Has $3.56 Million Holdings in AngioDynamics, Inc. (NASDAQ:ANGO)

Connor Clark & Lunn Investment Management Ltd. grew its stake in AngioDynamics, Inc. (NASDAQ:ANGO - Free Report) by 69.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 389,053 shares of the medical instruments supplier's stock after acquiring an additional 158,897 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned 0.96% of AngioDynamics worth $3,564,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of the stock. SBI Securities Co. Ltd. acquired a new stake in shares of AngioDynamics during the 4th quarter worth approximately $28,000. R Squared Ltd acquired a new position in AngioDynamics during the fourth quarter valued at approximately $49,000. US Bancorp DE grew its holdings in AngioDynamics by 1,938.0% during the fourth quarter. US Bancorp DE now owns 6,705 shares of the medical instruments supplier's stock valued at $61,000 after purchasing an additional 6,376 shares during the period. Quarry LP grew its holdings in AngioDynamics by 40.9% during the third quarter. Quarry LP now owns 8,518 shares of the medical instruments supplier's stock valued at $66,000 after purchasing an additional 2,471 shares during the period. Finally, SG Americas Securities LLC boosted its holdings in shares of AngioDynamics by 21.3% in the fourth quarter. SG Americas Securities LLC now owns 16,102 shares of the medical instruments supplier's stock valued at $147,000 after buying an additional 2,832 shares during the period. 89.43% of the stock is owned by institutional investors.

AngioDynamics Price Performance

Shares of AngioDynamics stock traded up $0.05 on Friday, hitting $9.92. The company had a trading volume of 636,948 shares, compared to its average volume of 564,170. The firm has a market capitalization of $401.42 million, a P/E ratio of -1.76 and a beta of 0.56. AngioDynamics, Inc. has a twelve month low of $5.26 and a twelve month high of $13.50. The stock has a 50-day moving average of $10.70 and a 200-day moving average of $8.68.

Remove Ads

AngioDynamics (NASDAQ:ANGO - Get Free Report) last announced its quarterly earnings data on Wednesday, January 8th. The medical instruments supplier reported ($0.04) EPS for the quarter, topping analysts' consensus estimates of ($0.11) by $0.07. The business had revenue of $72.90 million for the quarter, compared to analyst estimates of $70.93 million. AngioDynamics had a negative net margin of 79.38% and a negative return on equity of 7.26%. The firm's revenue for the quarter was down .1% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.05) earnings per share. Equities analysts predict that AngioDynamics, Inc. will post -0.37 EPS for the current year.

Insiders Place Their Bets

In other AngioDynamics news, SVP Warren Nighan, Jr. sold 4,060 shares of the company's stock in a transaction on Thursday, January 16th. The shares were sold at an average price of $12.31, for a total value of $49,978.60. Following the transaction, the senior vice president now directly owns 41,817 shares in the company, valued at $514,767.27. The trade was a 8.85 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 5.40% of the company's stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright upped their price target on shares of AngioDynamics from $14.00 to $15.00 and gave the company a "buy" rating in a report on Friday, January 10th.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.